GW873140 In Combination With Kaletra In HIV Infected Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Infection, Human Immunodeficiency Virus IHIV Infection
Interventions
DRUG

GW873140

DRUG

Kaletra (lopinavir/ritonavir)

Trial Locations (70)

1150

GSK Investigational Site, Lisbon

2750

GSK Investigational Site, Cascais

10014

GSK Investigational Site, New York

10149

GSK Investigational Site, Turin

13005

GSK Investigational Site, Marseille

13353

GSK Investigational Site, Berlin

18103

GSK Investigational Site, Allentown

19102

GSK Investigational Site, Philadelphia

20007

GSK Investigational Site, Washington D.C.

20036

GSK Investigational Site, Washington D.C.

20099

GSK Investigational Site, Hamburg

20127

GSK Investigational Site, Milan

20146

GSK Investigational Site, Hamburg

20157

GSK Investigational Site, Milan

23666

GSK Investigational Site, Hampton

28034

GSK Investigational Site, Madrid

28209

GSK Investigational Site, Charlotte

30308

GSK Investigational Site, Atlanta

30339

GSK Investigational Site, Atlanta

32804

GSK Investigational Site, Orlando

33306

GSK Investigational Site, Fort Lauderdale

33308

GSK Investigational Site, Fort Lauderdale

33408

GSK Investigational Site, West Palm Beach

33614

GSK Investigational Site, Tampa

33901

GSK Investigational Site, Fort Myers

34205

GSK Investigational Site, Bradenton

39202

GSK Investigational Site, Jackson

41013

GSK Investigational Site, Seville

44093

GSK Investigational Site, Nantes

50937

GSK Investigational Site, Cologne

53127

GSK Investigational Site, Bonn

59208

GSK Investigational Site, Tourcoing

60590

GSK Investigational Site, Frankfurt am Main

60613

GSK Investigational Site, Chicago

60657

GSK Investigational Site, Chicago

70115

GSK Investigational Site, New Orleans

75018

GSK Investigational Site, Paris

75475

GSK Investigational Site, Paris

75571

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

75679

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

77027

GSK Investigational Site, Houston

80220

GSK Investigational Site, Denver

85006

GSK Investigational Site, Phoenix

85745

GSK Investigational Site, Tucson

87505

GSK Investigational Site, Santa Fe

90027

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

90813

GSK Investigational Site, Long Beach

92708

GSK Investigational Site, Fountain Valley

93205

GSK Investigational Site, Saint-Denis

94275

GSK Investigational Site, Le Kremlin-Bicêtre

94804

GSK Investigational Site, Villejuif

97209

GSK Investigational Site, Portland

94115-1931

GSK Investigational Site, San Francisco

70127-0800

GSK Investigational Site, New Orleans

V6Z 2C7

GSK Investigational Site, Vancouver

L8N 3Z5

GSK Investigational Site, Hamilton

K1H 8L6

GSK Investigational Site, Ottawa

M5G 2N2

GSK Investigational Site, Toronto

G1V 4G2

GSK Investigational Site, Sainte-Foy

DK-2100

GSK Investigational Site, Copenhagen

DK-2650

GSK Investigational Site, Hvidovre

1066 EC

GSK Investigational Site, Amsterdam

M8 5RB

GSK Investigational Site, Manchester

BN2 1ES

GSK Investigational Site, Brighton

B29 6JD

GSK Investigational Site, Birmingham

EC1 7BE

GSK Investigational Site, London

NW3 2QG

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY